Barclays Has Lowered Expectations for Medpace (NASDAQ:MEDP) Stock Price

Medpace (NASDAQ:MEDP) had its price objective dropped by research analysts at Barclays from $525.00 to $500.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has an “underweight” rating on the stock. Barclays‘s target price would indicate a potential upside of 16.94% from the stock’s current price.

MEDP has been the subject of several other reports. Wall Street Zen upgraded Medpace from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. Truist Financial cut their price objective on shares of Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a research note on Wednesday. Mizuho set a $660.00 price target on shares of Medpace in a report on Friday, January 9th. BMO Capital Markets set a $460.00 price objective on Medpace in a research note on Wednesday. Finally, Robert W. Baird raised Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 target price on the stock in a report on Tuesday. Three investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, Medpace has a consensus rating of “Hold” and a consensus price target of $484.45.

Medpace Trading Down 4.1%

NASDAQ:MEDP opened at $427.58 on Wednesday. Medpace has a twelve month low of $250.05 and a twelve month high of $628.92. The company has a market cap of $12.04 billion, a PE ratio of 28.11, a P/E/G ratio of 1.78 and a beta of 1.42. The company’s 50 day moving average is $575.55 and its two-hundred day moving average is $539.56.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Monday, February 9th. The company reported $4.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.18 by $0.49. The business had revenue of $708.45 million during the quarter, compared to analysts’ expectations of $689.53 million. Medpace had a net margin of 17.83% and a return on equity of 127.72%. The business’s quarterly revenue was up 32.0% on a year-over-year basis. During the same quarter last year, the company posted $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, analysts expect that Medpace will post 12.29 EPS for the current fiscal year.

Insider Buying and Selling

In other Medpace news, VP Susan E. Burwig sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $609.15, for a total value of $12,183,000.00. Following the sale, the vice president directly owned 27,500 shares of the company’s stock, valued at approximately $16,751,625. This trade represents a 42.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO August J. Troendle sold 59,025 shares of the stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $607.78, for a total value of $35,874,214.50. Following the transaction, the chief executive officer owned 774,602 shares in the company, valued at $470,787,603.56. This trade represents a 7.08% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 296,880 shares of company stock worth $178,815,404 in the last quarter. 20.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Medpace

Several institutional investors have recently bought and sold shares of the company. NewEdge Advisors LLC boosted its holdings in shares of Medpace by 22.1% during the 1st quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock worth $319,000 after purchasing an additional 190 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Medpace by 3.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock worth $24,929,000 after acquiring an additional 3,010 shares during the period. Geneos Wealth Management Inc. grew its holdings in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares during the period. Sivia Capital Partners LLC purchased a new position in Medpace during the second quarter worth about $296,000. Finally, IFP Advisors Inc boosted its holdings in Medpace by 223.3% in the 2nd quarter. IFP Advisors Inc now owns 194 shares of the company’s stock valued at $61,000 after purchasing an additional 134 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace News Roundup

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Robert W. Baird upgraded MEDP from “neutral” to “outperform” and set a $564 price target, signaling renewed buy-side enthusiasm. Baird Upgrade
• Positive Sentiment: Medpace won a CRO contract from Zelluna to run the first‑in‑human trial for ZIMA‑101 — a new business‑development win that supports future revenue pipeline. Zelluna CRO Win
• Positive Sentiment: Q4 results and FY2026 guidance beat/raise: Q4 EPS $4.67 vs $4.18 est., revenue $708.5M (up 32% YoY). Management set FY‑2026 EPS guidance of $16.68–$17.50 and revenue $2.8–2.9B, above consensus — supportive for forward earnings expectations. Earnings Release
• Neutral Sentiment: Truist trimmed its PT slightly to $539 and kept a “hold” rating — a modest change that is less bearish than some other dealer moves. Truist Note
• Neutral Sentiment: Market commentary highlights a strong quarter but flags a slow backlog — analysts note book‑to‑bill strength but a “stale backlog” that could limit upside until sales acceleration resumes. SA Analysis
• Negative Sentiment: Leerink Partners cut its price target from $575 to $485 and moved MEDP to “market perform,” which likely pressured sentiment given the size of the cut. Leerink PT Cut
• Negative Sentiment: Shares fell intraday despite the beat — headlines and analyst caution on backlog/growth cadence triggered a roughly 5% pullback as traders digested the guidance details and valuation. Investing.com
• Negative Sentiment: Coverage pieces called out a “key negative” element that tempered the headline beat (backlog normalization and shifts in metabolic trials), which investors are parsing for sustainability of revenue growth. MSN

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.